“减肥神药”跨界梦碎！口服Ozempic治疗阿兹海默症宣告失败，诺和诺德暴跌12%

Core Viewpoint - Novo Nordisk's attempt to develop an oral version of Ozempic for Alzheimer's disease has failed in two large clinical trials, leading to a significant drop in its stock price and concerns about its long-term competitiveness in the obesity treatment market [1][5]. Group 1: Clinical Trial Results - The clinical trials did not show significant improvement in cognitive assessments for patients taking the drug, leading to the termination of a planned one-year extension study [1]. - The trials tracked over 3,500 patients with mild Alzheimer's disease, and while some physiological indicators showed improvement, it did not translate into a significant slowdown in disease progression [5]. Group 2: Market Reaction - Following the announcement, Novo Nordisk's stock price fell by as much as 12.4%, reaching its lowest level since July 2021, with a cumulative decline of over 50% this year [1][5]. - Competitor Eli Lilly's stock also dropped in pre-market trading, while Biogen, focused on Alzheimer's drug development, saw a 6.7% increase in its stock price [4]. Group 3: Financial Implications - Morgan Stanley analysts estimated that if the trials had been successful, the drug could have generated up to $5 billion in annual revenue for Novo Nordisk [4]. - The probability of success for the trials was estimated at 25%, with a failure probability of 75%, indicating the high-risk nature of the project [5].